Form 4: ALX Oncology CEO Jason Lettmann Reports Tax-Related Stock Disposal
SEC Form 4 Filing
CEO Jason Lettmann of ALX Oncology Holdings Inc. reports the disposal of shares to cover tax obligations related to vested restricted stock units.
Summary
- On August 14, 2024, Jason Lettmann, CEO of ALX Oncology Holdings Inc., disposed of 2,191 shares of common stock to cover tax liabilities associated with the vesting of restricted stock units (RSUs).
- The shares were sold at a price of $2.58 per share.
- Following the transaction, Lettmann directly owns 169,429 shares of ALX Oncology common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing indicates a routine transaction to cover tax obligations, which is a normal part of executive compensation. It doesn't necessarily reflect a positive or negative outlook on the company's performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like CEOs, buy or sell their company's stock. These filings provide transparency into insider transactions and can be scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. Disposals to cover tax obligations are common and don't necessarily indicate a negative outlook.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date of stock disposal transaction |
| 08/16/2024 | Date of signature on the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.